Navigation Links
Sancilio Pharmaceuticals Company, Inc. Announces Completion of Enrollment in the SCOT Trial in Pediatric Patients With Sickle Cell Disease Using Altemia Capsules
Date:7/26/2017

RIVIERA BEACH, Fla., July 26, 2017 /PRNewswire/ -- Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced the completion of enrollment of our clinical trial evaluating AltemiaTM, an oral therapy for pediatric patients with Sickle Cell Anemia (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, is a double-blind, placebo-controlled, dose-finding, multi-center study to evaluate the efficacy and safety of AltemiaTM in pediatric patients aged 5-17 years old. This trial is conducted under US IND 125274.

"The completion of enrollment in this study represents an important milestone for SPCI and our lead program for SCA and SCD," said Dr. Fred Sancilio, President and Chief Executive Officer of SPCI. "We are very encouraged by the high retention rate and adherence to treatment seen thus far in the study.  This study will further our understanding of the impact of AltemiaTM on Sickle Cell Disease."

Adrian L. Rabinowicz, M.D, SPCI's Chief Medical Officer, stated, "The faster than expected enrollment in this study highlights the intense interest and enthusiasm of the investigators, their staffs, as well as the patients and their families in achieving this important step for our development program. We look forward to reporting top-line results from the study early Q4 this year."

For more information about the SCOT Trial, please visit https://clinicaltrials.gov/ct2/show/NCT02973360.

For more information about AltemiaTM, please visit Altemia4sicklecell.com.

About Sickle Cell Disease

Sickle Cell Disease (SCD) and Sickle Cell Anemia (SCA) are a group of genetic disorders that result in dysfunctional hemoglobin and a depletion of certain fatty acids in the membrane of red and white blood cells. These abnormalities increase the red and white blood cells tendency to adhere to each other, which results in episodic occlusions of blood vessels, reperfusion damage, and excruciating pain. Ultimately, many children develop end organ damage and strokes. There are approximately 100,000 cases of SCD in the United States and millions outside of the United States.  Treatment options are limited.

About Sancilio Pharmaceuticals Company, Inc.

Sancilio Pharmaceuticals Company, Inc. (SPCI) is a fully integrated, specialty pharmaceutical company focused on developing, manufacturing and commercializing pharmaceutical products, including those based on our proprietary Advanced Lipid Technologies® (ALT®) platform. SPCI is pursuing treatments for sickle cell disease, short bowel syndrome and severe hypertriglyceridemia. We utilize our cGMP compliant facility to develop and manufacture our products. Our ALT® platform is designed to enhance the bioavailability, reduce the food effect and improve the efficacy of lipids and lipophilic active pharmaceutical ingredients (APIs). Lipids are hydrophobic or amphipathic molecules, including fatty acids, steroids (including hormones) and fat-soluble vitamins (such as vitamins A, D, E and K). Our business model is to apply our ALT® platform to lipids or lipophilic APIs to create unique product candidates that address the disorders and diseases resulting from imbalances of lipids in the body. In addition to our primary focus of developing our proprietary products using the ALT® platform, we make use of, and license rights to, our proprietary ALT® platform and other technologies to third parties, providing both development and subsequent soft gelatin encapsulation services. More information is available at Sancilio.com.

Contacts
Sancilio Pharmaceuticals Company, Inc.
Marc Wolff, 561-847-2302
Executive Vice President & Chief Financial Officer

Related Links

Sancilio Pharmaceuticals

View original content with multimedia:http://www.prnewswire.com/news-releases/sancilio-pharmaceuticals-company-inc-announces-completion-of-enrollment-in-the-scot-trial-in-pediatric-patients-with-sickle-cell-disease-using-altemia-capsules-300494609.html


'/>"/>
SOURCE Sancilio Pharmaceuticals Company, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
2. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
3. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
4. Access Pharmaceuticals Reports First Quarter Results
5. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
6. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
7. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
8. Aveo Pharmaceuticals, Inc. Sued by Investor
9. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm
10. Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology
11. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2018)... ... 16, 2018 , ... AMGtime will be exhibiting at the ... At booth 1940, AMGtime will showcase time, labor management, and scheduling solutions including ... specialized Skilled Nursing Facility module . , Designed to appease common pain ...
(Date:10/13/2018)... ... October 12, 2018 , ... David Young ... which was used in the Lockheed F22 Aircraft. Today, he announces the invention ... AF-Arrhythmia, which can lead to sudden cardiac death (SCD). , The Two-Dimensional Arrhythmia ...
(Date:10/11/2018)... ... October 11, 2018 , ... ... today that it has completed the strategic combination of RevSpring and Apex ... revenue cycle engagement, billing, and payments solutions generating over one billion consumer ...
Breaking Medicine Technology:
(Date:10/13/2018)... ... 12, 2018 , ... At HEI Health, we believe tomorrow’s healthcare can be ... year’s National Healthcare CXO Fall Summit by Marcus Evans. HEI will be hosting an ... Experience challenges with leading healthcare providers. , Marcus Evans National Healthcare CXO Summit ...
(Date:10/13/2018)... Mo. (PRWEB) , ... October 12, 2018 , ... Convoy ... hardest-hit communities. Convoy of Hope has a distribution site set up to serve hurricane ... , , Up to 50 additional truckloads of supplies are ...
(Date:10/13/2018)... , ... October 13, 2018 , ... ... on Sports, Fitness & Nutrition, has announced LaRhonda Burley as its new Vice ... congressionally chartered in 2010 to support and strengthen the mission of the President's ...
(Date:10/11/2018)... (PRWEB) , ... October 11, 2018 , ... ... for 2018. The medalists are leading scientists in their fields recognized by DuPont ... advancing science and technology relevant to the future of food, nutrition and health. ...
(Date:10/11/2018)... ... October 11, 2018 , ... ... quite vulnerable to manipulation,” warns former U.S. Department of Homeland Security deputy assistant ... Vulnerable and How We Can Stop it. , Pointing to the ability of ...
Breaking Medicine News(10 mins):